A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Fang Zheng, Yanwen Zhou, Zhiguo Zhou, Fei Ye, Baoying Huang, Yaxiong Huang, Jing Ma, Qi Zuo, Xin Tan, Jun Xie, Peihua Niu, Wenlong Wang, Yun Xu, Feng Peng, Ning Zhou, Chunlin Cai, Wei Tang, Xinqiang Xiao, Yi Li, Zhiguang Zhou, Yongfang Jiang, Yuanlin Xie, Wenjie Tan, Guozhong Gong
doi: https://doi.org/10.1101/2020.04.24.20077735
Fang Zheng
aDepartment of Infectious Diseases, the First Hospital of Changsha, Changsha, Hunan, China
Yanwen Zhou
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Zhiguo Zhou
bDepartment of Respiratory Medicine, the First Hospital of Changsha, Changsha, Hunan, China
Fei Ye
hNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
Baoying Huang
hNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
Yaxiong Huang
aDepartment of Infectious Diseases, the First Hospital of Changsha, Changsha, Hunan, China
Jing Ma
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Qi Zuo
cDepartment of Intensive Care Unit, the First Hospital of Changsha, Changsha, Hunan, China
Xin Tan
dDepartment of pediatrics, the First Hospital of Changsha, Changsha, Hunan, China
Jun Xie
eDepartment of Internal Medicine, the First Hospital of Changsha, Changsha, Hunan, China
Peihua Niu
hNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
Wenlong Wang
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Yun Xu
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Feng Peng
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Ning Zhou
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Chunlin Cai
aDepartment of Infectious Diseases, the First Hospital of Changsha, Changsha, Hunan, China
Wei Tang
aDepartment of Infectious Diseases, the First Hospital of Changsha, Changsha, Hunan, China
Xinqiang Xiao
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Yi Li
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Zhiguang Zhou
gKey Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Yongfang Jiang
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Yuanlin Xie
aDepartment of Infectious Diseases, the First Hospital of Changsha, Changsha, Hunan, China
Wenjie Tan
hNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
Guozhong Gong
fDepartment of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
After formal publication, data related to study protocol, statistical analysis plan, etc. will be made available to others with reasonable written request to corresponding authors. The requests will be evaluated, and data provided on the basis of reasonability, detailed study design and protocol, permission of legal and government rules, and approval from the study participating institutes.
Posted April 29, 2020.
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Fang Zheng, Yanwen Zhou, Zhiguo Zhou, Fei Ye, Baoying Huang, Yaxiong Huang, Jing Ma, Qi Zuo, Xin Tan, Jun Xie, Peihua Niu, Wenlong Wang, Yun Xu, Feng Peng, Ning Zhou, Chunlin Cai, Wei Tang, Xinqiang Xiao, Yi Li, Zhiguang Zhou, Yongfang Jiang, Yuanlin Xie, Wenjie Tan, Guozhong Gong
medRxiv 2020.04.24.20077735; doi: https://doi.org/10.1101/2020.04.24.20077735
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Fang Zheng, Yanwen Zhou, Zhiguo Zhou, Fei Ye, Baoying Huang, Yaxiong Huang, Jing Ma, Qi Zuo, Xin Tan, Jun Xie, Peihua Niu, Wenlong Wang, Yun Xu, Feng Peng, Ning Zhou, Chunlin Cai, Wei Tang, Xinqiang Xiao, Yi Li, Zhiguang Zhou, Yongfang Jiang, Yuanlin Xie, Wenjie Tan, Guozhong Gong
medRxiv 2020.04.24.20077735; doi: https://doi.org/10.1101/2020.04.24.20077735
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2599)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12134)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4028)
- Geriatric Medicine (379)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (358)
- HIV/AIDS (831)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (563)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6469)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)